Sourcery: Nworah Ayogu on AI, Brain Tech, and Healthcare’s ChatGPT Moment

SPEAKER_1 (0:01)

When healthcare, AI, and biology collide, the stakes get very real.

Let's talk about Molly O'Shea's conversation with Nworah Ayogu of Thrive Capital.

Right off the bat, Ayogu lays out something staggering: the United States has spent roughly $40 trillion on healthcare over the last 10 years, yet life expectancy hasn't improved. It's actually trending downward. That's a blunt indictment of the current system. But here's what's fascinating—Ayogu sees a turning point. AI is transforming everything from drug discovery to clinical trials to commercialization. He says the magic of AI in drug discovery lies in solving complex biological risks, from finding molecular targets to predicting off-target effects and real-world outcomes. And that leads to what I think is one of the most exciting parts: the bet on hardware plus biotech. Ayogu highlights companies like Neuralink and Foretell as solving problems of nearly biblical scale. We're talking about helping paralyzed patients move and mute patients speak. He actually calls the brain the fundamental substrate for all human achievement and says it's a more efficient engine than every chip Nvidia has ever made. Bold claim!

What's Foretell doing specifically? They're attacking hearing loss, which affects 1.5 billion people worldwide and is a major modifiable risk factor for dementia.

Traditional hearing aids just amplify everything. Foretell built custom hardware with semantic noise processing so users can follow a conversation in a loud room without drowning in background sound. That connects perfectly to this idea of "N of 1 medicine"— treatments tailored to one person at a time. Ayogu points to gene-edited treatment for a newborn with a rare ammonia-processing disorder, and personalized cancer vaccines that pair with checkpoint inhibitors like Keytruda. The same logic is shaping healthcare software. Take Cadence—they use connected devices and AI to monitor patients at home, escalating issues to clinicians when needed. Ayogu says that approach has cut hospitalizations, improved blood pressure control, and saved Medicare money.

What about adoption though? That's often where healthcare tech fails. Great question. Ayogu says doctors don't hate technology, they hate bad technology. That's why he's enthusiastic about Open Evidence, which he describes as a rare clinical tool doctors actually enjoy using. He says adoption reached two-thirds of physicians in just three years. And OpenAI is changing healthcare culture too. Ayogu recounts how skepticism faded in meetings after live demonstrations of the o1 reasoning model answering difficult New England Journal of Medicine cases correctly, where even expert doctors often struggle. The business implications are huge. Ayogu expects more large standalone healthcare companies, more acquisitions, and more incumbents moving fast. He points to Oscar Health's comeback and Thrive's work with Amazon Health. He even suggests OpenAI may already be one of the largest healthcare providers in America through the questions millions of people ask every week.

The big picture is clear. Healthcare is entering its own ChatGPT moment, where better tools could make medicine more personal, more efficient, and far more humane.